All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Looking to expand its glycogen synthase kinase-3 beta (GSK-3beta) inhibitor program, Northwestern University spinout Actuate Therapeutics Inc. has secured $21.7 million in a series B round led by Kairos Ventures. Defta Partners and Tech Coast Angels, with existing investor Bios Partners also participated in the round.